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Essay
Improving the Evidence Base for Trauma
Care: Progress in the International CRASH-2
Trial
The CRASH-2 Trial Collaborators
There is an urgent need to improve the
evidence base for trauma care. Large-
scale clinical trials can provide impor-
tant answers, but they depend on effec-
tive international collaboration. The
purpose of this article is to bring one
such trial, the CRASH-2 trial, to the
attention of physicians around the
world. The CRASH-2 trial, which is
currently under way (registered at
ISRCTN86750102), is a large placebo-
controlled trial being performed in
trauma patients at risk of signiﬁcant
haemorrhage. The trial examines the
effects of antiﬁbrinolytic treatment on
death and the need for blood trans-
fusion. If such a simple and widely
practicable treatment as the antiﬁbri-
nolytic agent tranexamic acid (TXA)
were shown to reduce blood loss after
trauma, thousands of trauma deaths
could be preventable worldwide. Fur-
thermore, large numbers of patients
would avoid the risks of blood trans-
fusion. The trial is now recruiting and
has already randomisedmore than 2,000
trauma patients. In this article, we
present an overview of the progress of
the trial and urge physicians working in
emergency care to consider joining this
international collaborative effort.
Background to the Trial
Between the ages of 5 and 45 years, trauma
is second only to HIV/AIDS as a cause of
death. Each year, worldwide, more than 3
million people die as a result of trauma,
many after reaching hospital [1]. Among
trauma patients who do survive to reach
hospital, excessive blood loss is a common
cause of death, accounting for nearly half
of in-hospital trauma deaths [2]. Central
nervous system injury and multi-organ
failure account for most of the rest, both
of which can be worsened by severe
bleeding [3]. It is well documented that
funding for trauma research is less than
for almost any other cause of human
suffering. A World Health Organization
study compared the level of research
funding with current and projected
(2020) disease burden. The results clearly
showed the relative under-funding of
research on injuries. A more recent study
from the United Kingdom shows that
injury remains the most under-funded of
all health issues [4,5].
Systemic antiﬁbrinolytic agents are
widely used in major surgery to reduce
surgical blood loss. A recent systematic
review [6] of randomised controlled trials
of antiﬁbrinolytic agents (mainly aproti-
nin or TXA) in elective surgical patients
identiﬁed 89 trials including 8,580 rand-
omised patients. The results of the system-
atic review showed that these treatments
reduced the numbers needing transfusion
by one-third, reduced the volume needed
per transfusion by one unit, and halved
the need for further surgery to control
bleeding (all differences were statistically
signiﬁcant).
We hypothesised that since the haemo-
static changes after injury are similar to
those after surgery, it is important to ﬁnd
out whether antiﬁbrinolytic agents sim-
ilarly reduce blood loss, the need for
transfusion, and mortality following trau-
ma. The CRASH-2 (clinical randomisation
of an antiﬁbrinolytic in signiﬁcant hae-
morrhage [7]) trial was designed to test
precisely this hypothesis. Once complete,
this trial will, to our knowledge, be one of
the largest clinical trials in trauma ever
conducted.
The trial aims to recruit 20,000 patients
worldwide, and recruitment began in May
2005. Recruitment is expected to be
complete in December 2009. At the time
of this writing, 2,200 patients have been
recruited and the CRASH-2 trial is al-
ready the largest clinical trial among
patients following trauma with signiﬁcant
ongoing haemorrhage.
Overview of Trial Design
CRASH-2 is a randomised, double-blind
placebo-controlled trial comparing TXA
with matching placebo (saline), the details
of which have been published elsewhere
[7]. TXA is the antiﬁbrinolytic of choice
because it is much less expensive than
others within the drug category, has been
used for many years, and is a simple
synthetic molecule that does not require
a test dose and has less risk of allergic
reactions. The dosing regimen is a load-
ing dose of 1 g of TXA or placebo in a
100-ml infusion over 10 minutes followed
by a maintenance infusion of 120 mg/
hour for 8 hours. In the emergency
situation, the administration of a ﬁxed
dose is more practicable because weigh-
DOI: 10.1371/journal.pctr.0010030.g001
Figure 1. Randomisation Rate for the First
1,500 Patients
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ing patients in such situations is difﬁcult.
Therefore, a dose within the dose range
that has been shown to inhibit ﬁbrinolysis
and provide clinical beneﬁt was selected
for CRASH-2.
All adult trauma patients who are
within 8 hours of their injury and have
either signiﬁcant haemorrhage (systolic
blood pressure less than 90 mmHg and/or
heart rate more than 110 beats per
minute), or who are considered to be at
risk of signiﬁcant haemorrhage, are eligi-
ble for trial entry if they appear to be at
least 16 years old. Although entry is
allowed for up to 8 hours after injury,
the earlier that patients can be treated
the better. There are no other pre-
speciﬁed exclusion criteria, as the funda-
mental eligibility criterion is the respon-
sible physician’s ‘‘uncertainty’’ about
using TXA in a particular adult with
traumatic haemorrhage. The use of sim-
ple entry criteria and the uncertainty
principle, as is recommended in the
context of large-scale trials, allows partic-
ipating physicians to use their clinical
judgement when deciding whether or not
to enroll patients in the trial, just as they
do in normal medical practice. This is
particularly appropriate in the context of
traumatic haemorrhage, in which it is
necessary to evaluate a range of clinical
signs (also taking into account remedial
measures such as ﬂuid resuscitation)
when establishing the presence or ab-
sence of major haemorrhage.
Obtaining Consent in Emergency
Situations
This trial involves a population likely to
have impaired consciousness due to their
injury, and situations where randomisa-
tion to treatment has to be completed in
the context of a clinical emergency. The
legal requirement for consent in this
population has made it difﬁcult to con-
duct the trial in some countries, especially
those that require prior consent from the
patient or a legally identiﬁed representa-
tive. All patients are randomised accord-
ing to consent procedures that adhere to
the legal and ethical requirements of each
country and in accordance with Interna-
tional Conference on Harmonisation
Good Clinical Practice E6 guidelines,
section 4.8.15 [8].
Randomisation
Patients are randomised in one of two
ways. Hospitals with reliable telephone
access through which the recruiting physi-
cians are able to provide baseline data in
English use the central telephone random-
isation service provided by the Clinical
Trial Service Unit (CTSU) in Oxford.
During the call, which lasts 2–3 minutes,
baseline data are collected and recorded
on the central computer. To achieve a
reasonable balance on the key prognostic
factors, the allocation used aminimisation
algorithm, balancing for sex, age (16–24
years, 25–34 years, 35 years and older),
hours since injury (1 hour or less, 1–3
hours, more than 3 hours), type of injury
(blunt or penetrating), Glasgow Coma
Scale (3, 4–5, 6–8, 9–12, 13–15), systolic
blood pressure (.89, 76–89, 50–75, 1–49,
0), respiratory rate (.29, 10–29, 6–9, 1–5,
0), central capillary reﬁll time (2 or less, 3–
4, 5 or more) and bearing in mind what
packs remain at that hospital. The allo-
cated treatment pack number is then
given and recorded on the trial entry
form. In hospitals in which physicians are
unable to use central randomisation, a
local pack system is used. At such hospi-
tals, baseline information is collected on
the trial entry form and the next consec-
utively numbered treatment pack is taken
from a box of eight packs.
Main Outcomes in CRASH-2
We speciﬁed the primary outcome meas-
ure for CRASH-2 as death in hospital
within 4 weeks of injury. Secondary
outcome measures are receipt of a blood
transfusion, the number of blood units
transfused, surgical intervention, and
occurrence of vascular events (stroke,
myocardial infarction, pulmonary embo-
lism, deep vein thrombosis). A simple
and widely practicable treatment that
Table 1. Baseline Characteristics
Category Characteristic Number Percentage
Gender Male 1,291 86
Female 209 14
Age (years) ,16 2 ,1
16–24 490 33
25–34 441 29
35–44 261 17
45–54 184 12
55–64 74 5
.64 48 3
Type of injury Blunt 735 49
Penetrating 417 28
Both 348 23
Systolic blood pressure (mm Hg) ,76 233 16
76–89 289 19
.89 978 65
Hours since injury 0–1 615 41
1–2 247 16
2–3 191 13
3–4 147 10
4–5 106 7
5–6 79 5
6–7 78 5
7–8 34 2
.8 3 0.2
DOI: 10.1371/journal.pctr.0010030.t001
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reduces blood loss following trauma
might prevent thousands of premature
trauma deaths each year and, secondly,
could reduce exposure to the risks of
blood transfusion. Blood is a scarce and
expensive resource, and major concerns
remain about the risk of transfusion-
transmitted infection. Trauma is com-
mon in parts of the world where the
safety of blood transfusion is not en-
sured. A study in Uganda estimated the
population-attributable fraction of HIV
acquisition as a result of blood trans-
fusion to be about 2%, although some
estimates are much higher [9]. Full
details of the data collection instruments
are available at http://www.crash2.lshtm.
ac.uk. In-hospital deaths, transfusion
requirements, and any complications
are recorded on a single-sided outcome
form that is completed entirely from the
hospital notes. No special trial-speciﬁc
investigations are required.
Trial Progress
The recruitment during the ﬁrst year of
the trial is shown in Figure 1. The ﬁrst
patient was enrolled in May 2005, and,
since then, more than 2,000 patients
have been recruited at 60 participating
hospitals, with a monthly recruitment
rate of 200 patients per month. A
further 60 hospitals have ethics commit-
tee approval, and many more have
applied to take part and are seeking
ethics committee approval. It is expected
that the remaining 18,000 patients (2,000
recruited during the pilot phase) will be
recruited over three years, with six
months for data analysis, report prepa-
ration, and dissemination. The data-
monitoring committee convened on 3
August 2006 and reviewed data for more
than 1,800 randomised patients. The
committee commended the collaborators
on the excellent recruitment, and it was
the view of the committee that ‘‘the
interim analyses provided no reason for
modifying the CRASH-2 protocol on the
basis of safety or efﬁcacy.’’
Table 1 shows the characteristics of the
ﬁrst 1,500 randomised patients. As ex-
pected, there were more males (1,291,
86%) than females (209, 14%). The
average age was 33 years (SD¼14, median
¼ 30). Just less than half of the patients
(49%) had blunt injury, 28% had pene-
trating injury, and 23% had both types.
The median systolic blood pressure was
90 mm Hg. The majority of patients
(70%) were randomised within three
hours after injury.
Outcomes to Date
By the end of May 2006, outcomes from
1,268 randomized patients had been re-
ceived. The outcome data included in-
hospital deaths, transfusion requirements,
number of units transfused, surgical in-
tervention, and occurrence of throm-
boembolic episodes. The outcomes for
this cohort of patients are shown in Table
2. The overall mortality rate was 19%,
which was very close to that anticipated in
the sample size estimates (20%). More
than half of the patients (59%) received a
blood transfusion. The prevalence of
thromboembolic complications was low
(less than 1%). Treatment compliance was
determined on the basis that the entire
treatment regimen was given. All rando-
mised patients received the loading dose,
and 93% received the maintenance (7%
of patients died before the maintenance
dose was completed).
Comment on the CRASH-2
Experience: Our Perspective on
Trauma Trials
Compared with the disease burden, there
is a dearth of clinical trials in trauma care
and the existing trials are small, contri-
buting to uncertainty about effectiveness
[10,11]. A major factor contributing to
the lack of clinical trial evidence is the
fact that funding for trauma research is
less than for almost any other cause of
human suffering.
Randomised controlled trials provide
strong evidence that antiﬁbrinolytics are
effective in reducing blood loss during
elective surgery, but to date there has
been only one small trial of the use of
antiﬁbrinolytics in reducing blood loss
after trauma. We intend that the CRASH-
2 trial will assess reliably the effect of the
early administration of the antiﬁbrino-
lytic TXA on mortality and transfusion
requirements in adult trauma patients
with signiﬁcant haemorrhage.
Following the successful completion of
the ﬁrst CRASH trial funded by the UK
Medical Research Council, there is a well-
established trial-coordinating team and a
network of some 400 collaborating hos-
pitals, many of which are now recruiting
patients into the CRASH-2 trial and
others that will start recruiting in the
coming months. Progress to date shows
that the trial procedures work efﬁciently,
that baseline event rates are similar to
those anticipated, and that physicians
around the world are very interested in
participating in this trial.
The trial collaborators have made an
outstanding contribution by ensuring
that CRASH-2 is already the largest
clinical trial in traumatic haemorrhage.
However, in order to achieve the CRASH-
2 trial objectives, many more participat-
ing hospitals are required. We invite
physicians from around the world to join
this international collaboration and, in
this way, to help build the evidence base
for trauma care. “
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